Puang Medical's IPO on the Beijing Stock Exchange has successfully passed the initial review.

On December 26, the result of the 48th review meeting of the 2025 listing committee of the Beijing Stock Exchange was announced, and Pu'ang Medical's IPO successfully passed. Pu'ang Medical plans to raise 395 million yuan in this IPO, which will be used for projects such as the construction of intelligent manufacturing production lines for puncture intervention medical devices, research and industrialization projects for minimally invasive intervention medical devices, etc. Since its establishment in 2013, the company has focused on diabetes care products, continuously developing and upgrading insulin pens, peripheral blood collection needles, insulin injectors and other diabetes care products. Among them, the insulin pen needle is the company's core competitive product.